AcelRx Pharma (NASDAQ: ACRX) reported Q1 EPS of ($0.34), $0.07 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $3.109 million versus the consensus estimate of $1.8 million.

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.